A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

Phase 3 Completed 757 enrolled Aldeyra Therapeutics, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of 0.25% Reproxalap Ophthalmic Solution in Subjects with Dry Eye Disease

Timeline

Start: 2021-01-26
Primary completion: 2022-10-11
Completion: 2022-10-11

Publications

Radcliffe NM, Sheppard J, Simmons B, Owen D, Nguyen A, Cavanagh B, Brady TC. Phase 3 Randomized Clinical Trial Evaluating the Safety of Reproxalap in Patients With Dry Eye Disease. Ophthalmol Ther. 2026 May;15(5):1807-1821. doi: 10.1007/s40123-026-01379-0. Epub 2026 Apr 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Reproxalap	Other / unclassified	0.25 %	Topical

A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

Summary

Timeline

Publications

Drugs

Indications